The Treg Directed Therapies Summit will take place in Boston on May 22-24, 2018
Valbonne, France, May 21, 2018, 5.45pm CEST
TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces it will participate and present at the first Treg Directed Therapies Summit to be held in Boston on May 22-24, 2018.
This summit, a first of its kind, will gather academic and industry experts in the field of Treg-based in vivo and ex vivo therapies development. The theme of the conference will be the discovery and production of stable, persistent and targeted Treg directed therapies that accelerate clinical development.
Pierre Heimendinger, PhD, VP Pharmaceutical Development of TxCell, will lead a workshop entitled “New Approaches to Improving Cell Yield, Process Efficiency and Therapeutic Potency in Clinical Regulatory T Cell Manufacturing Processes” (May 22, 1 pm EST). He will also chair a round table discussion entitled “Identify Key Manufacturing Considerations to Ensure Feasible Large Scale Clinical Trials” (May 24, 2.30 pm EST).
In the section titled “Comparison of Trafficking Approaches to Achieve Antigen Specific Tolerance”, Stéphane Boissel, CEO of TxCell, will present TxCell’ specific approach to engineer Tregs for autoimmunity, inflammation and transplantation (May 24, 3.40 pm EST).
“The cross-industry demand for this summit as well as the quality of the panels and of the audience is a demonstration of the growing interest for the therapeutic potential of regulatory T cells,” said Stéphane Boissel, CEO, TxCell. “With over a decade of experience in the biology of this cell population, and a unique engineered CAR Treg cell platform, we believe that TxCell is well positioned to benefit from this new momentum.”